key: cord-0874683-n93lghk3
authors: Gupta, Samiksha; Arora, Shreya; Gupta, Monica; Jesrani, Gautam
title: Dengue Myocarditis Complicated by COVID-19: A Case Report on Dual Viral Infection
date: 2021-08-10
journal: Cureus
DOI: 10.7759/cureus.17076
sha: 168e723d2ebbb3bc86c5dc68bf7bc08567f9305b
doc_id: 874683
cord_uid: n93lghk3

During the ongoing pandemic of coronavirus disease 2019 (COVID-19), it is crucial for clinicians to have an insight into the emerging co-infections. As the dengue virus (DENV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have related symptomatology, a high index of suspicion is required for prompt diagnosis of concurrent infections involving these two pathogens, especially in the areas endemic for tropical diseases, i.e., dengue fever (DF), malaria, enteric fever, chikungunya, leptospirosis, etc. In this report, we present the case of a middle-aged man from Northern India, who had DF with myocarditis, and was simultaneously found to have COVID-19 co-infection. The patient was managed as per the COVID-19 protocol and had a favorable outcome.

Novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a lethal global pandemic [1] . It exhibits varied clinical manifestations, potentially affecting every organ system, although fever remains a common symptom [2] . In India, dengue virus (DENV) infection, transmitted by Aedes aegypti, is one of the most common causes of acute undifferentiated febrile illness (AUFI) with endemicity, usually during the monsoon and post-monsoon seasons. The symptom profile consists of mild non-specific symptoms such as fever, malaise, and vomiting, making the clinical recognition of the disease laborious [3] . In rare cases, myocarditis can also be seen in the disease course of dengue fever (DF). Concurrent infection of COVID-19 and dengue myocarditis is rarely described in the current literature, and in this report, we describe one such presentation. Additionally, we review and describe the overlapping symptomatology in such co-infections, which is imperative for clinicians to recognize in clinical practice.

A 65-year-old man with no known comorbidities in the past presented to the emergency department with a history of high-grade fever and chills for four days, which was relieved with antipyretic medication. He also had a history of intermittent episodes of the passage of reddish urine, lasting for two days, which was not associated with abdominal pain or dysuria. At presentation, he had non-productive intermittent bouts of cough but denied any exposure to COVID-19 or tuberculosis patients. On examination, the patient had a temperature of 38.5 ºC, a regular pulse rate of 48 beats/minute, blood pressure of 90/64 mmHg, respiratory rate of 18/minute, and was maintaining an oxygen saturation of 97% on room air. He also had a generalized erythematous rash over the abdomen and lower limbs ( Figure 1) . The cardiovascular and respiratory examination did not reveal any abnormality. His electrocardiogram demonstrated sinus bradycardia ( Figure  2 ), but the chest radiograph revealed no cardiomegaly or lung pathology on presentation. On investigations, his complete blood profile revealed a total leucocyte count of 2.3 x 10 9 /L with 55% neutrophils and 40% lymphocytes and thrombocytopenia of 20 x 10 9 /L ( Table 1 ). In light of the thrombocytopenia, the patient was evaluated for malaria, scrub typhus, leptospirosis, enteric fever, and DF. DENV serology for immunoglobulin M (IgM) came out to be positive with test levels of 0.72 optical density (OD, cut-off value: 0.31) while DENV NS-1 antigen was negative by enzyme-linked immunoassay. Thrombocytopenic measures were advised (i.e., to avoid brushing teeth or straining and no intramuscular injection) along with intravenous fluid therapy. Due to relative bradycardia, the possibility of viral myocarditis was considered. His qualitative troponins were negative; however, creatine phosphokinase-MB (CPK-MB) was considerably high, i.e., 72 U/L (cut off value: <25), and N-terminal pro-B type natriuretic peptide (NT-proBNP) was 1560 pg/mL (cut off for age: <900 pg/mL). 2D-echocardiography showed normal left ventricular systolic function, grade-I diastolic dysfunction, and preserved ejection fraction of 64%. Regarding hematuria evaluation, his ultrasound of the renal system did not reveal any anatomical discrepancy or stones within the pelvicalyceal system and therefore it was attributed to severe thrombocytopenia.

Hemoglobin (g/dL) 12.0-16.0 13.0 13.4

Total leucocyte count (x 10 9 /L) 4.0-11.0 2. 3 

Neutrophil-lymphocyte ratio 1-3 1. 

On the fifth day of hospitalization, he developed breathlessness with a respiratory rate of 26/minute and a saturation of 90% on room air following which a repeat chest radiograph was performed, which suggested bilateral heterogeneous opacity in lower zones (left > right) and the left middle zone (Figure 3) . He was managed with oxygen supplementation through a venturi mask and had a normal oxygen saturation thereafter. High-resolution CT (HRCT) of the chest was done, which was suggestive of bilateral ground-glass opacities (left > right) and a severity index of 13/25 ( Figure 4) . In light of the ongoing pandemic and local protocol, the patient was tested via nasopharyngeal swab by reverse transcriptase-polymerase chain reaction (RT-PCR) for COVID-19, and he was confirmed positive for SARS-CoV-2 virus. Only intravenous steroids (0.1 mg/kg dexamethasone for seven days) could be given since anticoagulation was omitted due to thrombocytopenia. From day three onwards, the patient had gradual improvement in the heart rate, platelet count, and continued to have stable blood pressure. The patient was discharged successfully after 17 days in the hospital isolation facility with no residual symptoms on follow-up.

Numerous concerns have been raised regarding the co-infection of COVID-19 with endemic illnesses such as DF, scrub typhus, enteric fever, and leptospirosis. One of them pertains to similar presenting complaints like fever, malaise, headache, abdominal pain, or vomiting. Uncertainty and delay in diagnosis usually ensue due to the confounding clinical picture and, additionally, related to laboratory investigations for leucopenia and thrombocytopenia. Such co-infections add an additional burden to the already over-worked healthcare system in the present pandemic, especially in developing countries [4] . In our case, the patient presented with AUFI, fulfilling the laboratory criteria for DF. He subsequently tested positive for COVID-19 disease through nasopharyngeal swab by RT-PCR, prompted by the new-onset breathlessness.

Since the COVID-19 pandemic is still ongoing in Asia, which is a DENV endemic zone, co-infection of DENV and SARS-CoV-2 virus could be tricky, thereby leading to delay in the diagnosis. Although both are ribonucleic acid (RNA) viruses, they have varied pathophysiology and target organ involvement but eventually lead in the similar direction of cytokine release, resulting in dysfunction in the integrity of the vascular endothelium leading to vasculopathy, coagulopathy, and capillary leak [5] . The phenomenon of antibody-dependent enhancement (ADE) has been described for both viruses, resulting in acceleration in the degree of infection and incidence of complications [6] . Various animal studies have also shown a possible role of the angiotensin-II converting enzyme (ACE) and angiotensin in the pathophysiology of viruses such as DENV, SARS-CoV-2, and H7N9 influenza [7] .

The characteristics of both the viruses in terms of epidemiological and clinical presentation are shown in Table 2 [8] . A study by Yue et al. showed a huge overlap between clinical spectrums of both diseases, with fever and headache being the most common symptoms in both [2] . Our patient had presented with fever and bleeding manifestation with no respiratory and cardiovascular symptoms at presentation or no exposure to COVID-19, and hence the possibility for a tropical illness was significant. This calls for a high index of suspicion to test for other causes in the setting of one, especially in endemic areas during monsoon and post-monsoon seasons. Other than non-specific signs and symptoms, which present an unpredictable influence on the severity and clinical outcome of the patient, the co-infection presents with diagnostic challenges too. Serious precautions taken to prevent the spread of transmission of COVID-19 in a febrile patient can cause a potentially dangerous delay in the diagnosis of DF. Furthermore, the COVID-19 pandemic has led to global shortages in certain laboratory reagents. Since the molecular diagnosis of both COVID-19 and DENV requires the same extraction kits and enzymes, the depletion of stocks has escalated [9] . Misleading results due to cross-reaction between these two viruses have been reported in previous studies, demonstrating that antibodies to DENV envelope hypothetically binds to "receptor binding motif (RBM)" of the spike protein of SARS-CoV-2, with certain interactions diverting the binding of angiotensinconverting enzyme (ACE-2) receptor to RBM [10] .

Characteristics Dengue fever COVID-19 Dual viral infection of COVID-19 and DENV is not uncommon; it is a demanding condition, which requires a high index of suspicion. The symptoms may be non-specific in most of the cases and an individual can be asymptomatic till late in the disease course. The treating physician should be familiar with these clinical scenarios. Preventive measures like social distancing and cough etiquette implementation should be coupled with vector control and the use of insect repellents inside the hospital too. A concerted effort should be undertaken to prevent, diagnose, and treat this co-infection using vigilant measures, especially in endemic areas during rainy and post-rainy seasons.

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

COVID-19): a literature review

Clinical characteristics of coronavirus disease 2019 in Gansu province

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020

Covid-19 and dengue: double punches for dengue-endemic countries in Asia

Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

Coronavirus disease of 2019: a mimicker of dengue infection

Losartan and enalapril decrease viral absorption and interleukin 1 beta production by macrophages in an experimental dengue virus infection

Simultaneous dengue and COVID-19 epidemics: difficult days ahead

Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?